	US 7,544,476 B1
	Identifying cancers sensitive to treatment with inhibitors of notch signaling
Ronan O'Hagan, Arlington, Mass. (US); H. Heidi Okamura, Brookline, Mass. (US); Alisa C. Bell, Burlington, Mass. (US); and Jeanine Lorusso, Ashland, Mass. (US)
Assigned to AVEO Pharmaceuticals, Inc., Cambridge, Mass. (US)
Filed on Jan. 27, 2009, as Appl. No. 12/360,790.
Claims priority of provisional application 61/080122, filed on Jul. 11, 2008.
Int. Cl. C12Q 1/68 (2006.01)

U.S. Cl. 435—6

9 Claims

1. A method of identifying a human or mouse cancer tissue sensitive to treatment with an agent that inhibits Notch receptor activation, comprising:

(a) measuring the level of HeyL gene expression in a sample derived from the cancer tissue; and

(b) comparing the level of HeyL gene expression against a standard value, thereby identifying a cancer tissue sensitive to treatment with an agent that inhibits Notch receptor activation on the basis of HeyL gene expression alone, wherein an elevated level of HeyL gene expression in the sample indicates sensitivity of the cancer tissue to treatment with the agent.